CrystalGenomics, BexPharm deal

CrystalGenomics will merge with specialty pharma company BexPharm in a stock deal. BexPharm shares will be exchanged for new CrystalGenomics shares at a ratio of 1 CrystalGenomics share for every 0.97 BexPharm share. The combined company will retain CrystalGenomics name and location. The deal is expected to close by the end of August.

CrystalGenomics will gain BexPharm's sales and marketing infrastructure, which will allow the combined company to develop and commercialize drugs in Korea without the need for partnering. According to Crystal Genomics, BexPharm had 2009 sales of $13 million. BexPharm's marketed products include Lactitol, a soluble disaccharide to treat constipation and acute and chronic portal systemic encephalopathy. ...